There is a lack of standards for diagnosing and treating nail psoriasis, a situation needing attention because the condition is often a precursor to psoriatic arthritis.
Authors of a literature review on nail psoriasis said attention is needed to the diagnosis and treatment of nail psoriasis because consistent standards are lacking even though the condition is often a precursor to psoriatic arthritis (PsA).
In a study published in The Journal of Rheumatology, findings from 66 articles on systemic therapies for treatment of nail psoriasis in psoriatic disease found several scoring systems in use, including varied subtypes and application of the Nail Psoriasis Severity Index. The authors said the finding highlighted the need for a common clinical measure to allow for comparative studies.
Psoriasis is a chronic inflammatory disease that affects approximately 2%-3% of the population. An estimated 40%-50% of psoriasis patients have psoriatic nail disease, with as many as 90% afflicted by it over their lifetimes. Nail psoriasis is problematic in and of itself because of the severe pain it can cause and its effect on quality of life, with patients often struggling with basic tasks such as putting on shoes or socks and other daily household activities. Many find the condition embarrassing and feel stigmatized for having what is perceived as a disfiguring disease.
Patients with nail psoriasis are almost 3 times as likely to developing PsA than those who do not have it. The authors said advances in diagnostic techniques have led to greater understanding of that link. There is a “mini-enthesis network” where the extensor tendon that crosses the distal interphalangeal (DIP) joint is fused with the nail matrix and nail root. Enthesitis is inflammation where tendons and ligaments meet bones and is one form of PsA.
“This may explain why patients with PsA, who usually present with enthesitis of the DIP joint, also frequently (although not always) present with nail changes characteristic of [nail psoriasis] NP,” the authors wrote.
The fingernail Physician’s Global Assessment is used to assess for nail plate pitting, crumbling, detachment from the nail bed, and/or thickening of the nail bed on a 5-point scale. The Nail Psoriasis Severity Index is the most widely used for scoring nail psoriasis in clinical trials, dividing each nail into 4 quadrants, with scoring based on presence or absence of psoriatic changes. A modified version of the scale has been created as well; there are also 5 other nail scoring systems. The variability of systems, which generally were meant for use in clinical trials, not daily practice, is problematic, the authors said.
The authors highlighted the need for a common clinical measure as studies proceed. However, longer trials may be necessary to judge them because of the slow growth of nails versus skin.
Given the limited research into nail psoriasis, it can be challenging to determine an appropriate course of treatment, the authors found. Topical therapies have only modest effect. Intralesional injection of corticosteroids or methotrexate directly into the nail matrix can be effective but is painful and time consuming. Oral therapies such as cyclosporine, methotrexate, acitretin (Soriatane), and leflunomide (Arava) have only modest effect and are often considered inappropriate for nail psoriasis.
Biologic and small-molecule therapies approved for treating PsA—including targeted inhibitors of tumor necrosis factor, interleukin (IL)-12/23, IL-17A, IL-23, phosphodiesterase 4, and Janus kinases—are effective for psoriatic skin or joint disease, but there is no specific indication for nail psoriasis and patients may not be able to get insurance to cover the drugs, the authors said.
Reference
Kaeley GS, Eder L, Aydin SZ, et al. Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs. J Rheumatol. 2021;48(3). doi:10.3899/jrheum.201471
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More